Technical Analysis for GTBP - GT Biopharma Inc.

Grade Last Price % Change Price Change
grade F 0.18 -10.85% -0.0219
GTBP closed down 10.85 percent on Friday, August 23, 2019, on 43 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GTBP trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Bullish Engulfing Bullish -10.85%
Crossed Above 20 DMA Bullish -10.85%
Wide Bands Range Expansion -10.85%
20 DMA Resistance Bearish 5.88%
Stochastic Reached Oversold Weakness 5.88%
Wide Bands Range Expansion 5.88%
Oversold Stochastic Weakness 5.88%
Fell Below 20 DMA Bearish 0.00%

Older signals for GTBP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.
Cancer Pain Immunology Immune System Monoclonal Antibodies Cancer Immunotherapy Technology Platforms Stage Biopharmaceutical Biochemistry Motion Sickness Cancer Therapies Immuno Oncology Products Myasthenia Gravis
Is GTBP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.39
52 Week Low 0.1681
Average Volume 86,354
200-Day Moving Average 0.4925
50-Day Moving Average 0.2233
20-Day Moving Average 0.1958
10-Day Moving Average 0.1897
Average True Range 0.0308
ADX 13.22
+DI 15.907
-DI 12.7907
Chandelier Exit (Long, 3 ATRs ) 0.1676
Chandelier Exit (Short, 3 ATRs ) 0.2605
Upper Bollinger Band 0.2334
Lower Bollinger Band 0.1582
Percent B (%b) 0.29
BandWidth 38.406537
MACD Line -0.0111
MACD Signal Line -0.0124
MACD Histogram 0.0013
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2288
Resistance 3 (R3) 0.2308 0.2167 0.2206
Resistance 2 (R2) 0.2167 0.2043 0.2156 0.2179
Resistance 1 (R1) 0.1983 0.1966 0.2075 0.1963 0.2152
Pivot Point 0.1842 0.1842 0.1888 0.1831 0.1842
Support 1 (S1) 0.1658 0.1718 0.1750 0.1638 0.1448
Support 2 (S2) 0.1517 0.1641 0.1506 0.1421
Support 3 (S3) 0.1333 0.1517 0.1394
Support 4 (S4) 0.1313